Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBS III-TT Vaccine to Prevent Vaginal Acquisition of GBS Type III
NCT00128219Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2003
- Primary completion
- Dec 2008
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GBS III-TT in group B streptococcal infection (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Time to First Vaginal Swab That is Type III GBS Culture Positive at 18 months. Started Jul 2003; status: completed.
02
Drugs
GBS III-TT
03
Conditions
group B streptococcal infection
Beyond the preview
Go deeper on NCT00128219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00128219.